2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC)
Can Urol Assoc J
.
2022 Nov;16(11):E506-E515.
doi: 10.5489/cuaj.8161.
Authors
Fred Saad
1
,
Armen Aprikian
2
,
Antonio Finelli
3
,
Neil E Fleshner
3
,
Martin Gleave
4
,
Anil Kapoor
5
,
Tamim Niazi
6
,
Scott A North
7
,
Fréderic Pouliot
8
,
Ricardo A Rendon
9
,
Bobby Shayegan
5
,
Srikala S Sridhar
10
,
Alan I So
4
,
Nawaid Usmani
11
,
Eric Vigneault
12
,
Kim N Chi
13
Affiliations
1
Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
2
McGill University Health Centre, Montreal, QC, Canada.
3
Division of Urology, University of Toronto, Toronto, ON, Canada.
4
Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.
5
Department of Surgery (Urology) and Oncology, McMaster University, Hamilton, ON, Canada.
6
Jewish General Hospital, Montreal, QC, Canada.
7
Department of Medical Oncology, University of Alberta, Edmonton, AB, Canada.
8
CHU de Quebec, Université Laval, Quebec City, QC, Canada.
9
Department of Urology, Dalhousie University, Halifax, NS, Canada.
10
Division of Medical Oncology, University of Toronto, Toronto, ON, Canada.
11
Department of Oncology, Division of Radiation Oncology, University of Alberta, Edmonton, AB, Canada.
12
Department of Radiation Oncology, CHU de Quebec, Université Laval, Quebec City, QC, Canada.
13
BC Cancer Agency, Vancouver, BC, Canada.
PMID:
36378572
PMCID:
PMC9665314
DOI:
10.5489/cuaj.8161
No abstract available